Sun BioPharma, Inc. Presents SBP-101 Phase 1 Clinical Data (BioSpace)

Sun BioPharma, Inc. Presents SBP-101 Phase 1 Clinical Data

UF startup Sun BioPharma, Inc., a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of people with pancreatic cancer, summarized initial Phase 1 clinical data for SBP-101, which was presented in a poster session at the American Society for Clinical Oncology (ASCO) 2020 Gastrointestinal Cancers Symposium. SBP-101 is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI), a metabolic pathway of critical importance in cell function in multiple tumor types. Based upon the study data presented, the adverse event profile of SBP-101 at the optimal dose level was manageable and an expansion study in patients with pancreatic ductal adenocarcinoma (PDA) is planned to begin during the second quarter of 2020.

“We are excited about the early results from this Phase 1 trial, which suggest improved activity of SBP-101 in combination with gemcitabine and nab-paclitaxel, along with a tolerable adverse event profile,” said Dr. Dusan Kotasek, director of clinical research at Adelaide Cancer Centre and a key principal investigator in both the monotherapy and combination therapy studies of SBP-101. “Pancreatic ductal adenocarcinoma is an area of incredibly high unmet medical need, and by evaluating SBP-101 with the current standard of care, we hope to be able to offer patients an improved therapeutic option.”

Learn more about Sun BioPharma, Inc. Presents SBP-101 Phase 1 Clinical Data.